Blocking antibodies against CD47 and methods of use thereof
AssigneeAccurus Biosciences, Inc.
InventorsHaishan Lin, Yi Zhang
Life of this patent
Estimating the term…
Abstract
Provided are anti-CD47 antibodies or fragments thereof that can bind to the extra cellular domain of the CD47 protein. The antibodies or fragments thereof can effectively block the interaction between human CD47 and its ligand SIRP alpha and enhance the phagocytosis activity of macrophages to engulf cancer cells. Some of these antibodies or fragments do not induce in vitro hemagglutination and therefore can be suitably used as therapeutic agents with reduced off-target effects.
Claims17
An antibody or fragment thereof having binding specificity to a human CD47 (cluster of differentiation 47) protein, wherein the antibody or fragment thereof comprises a light chain variable region comprising light chain complementarity determining regions CDRL1, CDRL2, and CDRL3 and a heavy chain variable region comprising heavy chain complementarity determining regions CDRH1, CDRH2, and CDRH3, and wherein
- the CDRL1 comprises the amino acid sequence of SEQ ID NO:25, the CDRL2 comprises the amino acid sequence YTS, the CDRL3 comprises the amino acid sequence of SEQ ID NO:27, the CDRH1 comprises the amino acid sequence of SEQ ID NO:28, the CDRH2 comprises the amino acid sequence of SEQ ID NO:29, and the CDRH3 comprises the amino acid sequence of SEQ ID NO:30,
- the CDRL1 comprises the amino acid sequence of SEQ ID NO:1, the CDRL2 comprises the amino acid sequence EGN, the CDRL3 comprises the amino acid sequence of SEQ ID NO:3, the CDRH1 comprises the amino acid sequence of SEQ ID NO:4, the CDRH2 comprises the amino acid sequence of SEQ ID NO:5, and the CDRH3 comprises the amino acid sequence of SEQ ID NO:6,
- the CDRL1 comprises the amino acid sequence of SEQ ID NO:7, the CDRL2 comprises the amino acid sequence YTS, the CDRL3 comprises the amino acid sequence of SEQ ID NO:9, the CDRH1 comprises the amino acid sequence of SEQ ID NO:10, the CDRH2 comprises the amino acid sequence of SEQ ID NO:11, and the CDRH3 comprises the amino acid sequence of SEQ ID NO:12,
- the CDRL1 comprises the amino acid sequence of SEQ ID NO:13, the CDRL2 comprises the amino acid sequence WAS, the CDRL3 comprises the amino acid sequence of SEQ ID NO:15, the CDRH1 comprises the amino acid sequence of SEQ ID NO:16, the CDRH2 comprises the amino acid sequence of SEQ ID NO:17, and the CDRH3 comprises the amino acid sequence of SEQ ID NO:18,
- the CDRL1 comprises the amino acid sequence of SEQ ID NO:19, the CDRL2 comprises the amino acid sequence YTS, the CDRL3 comprises the amino acid sequence of SEQ ID NO:21, the CDRH1 comprises the amino acid sequence of SEQ ID NO:22, the CDRH2 comprises the amino acid sequence of SEQ ID NO:23, and the CDRH3 comprises the amino acid sequence of SEQ ID NO:24, or
- the CDRL1 comprises the amino acid sequence of SEQ ID NO:31, the CDRL2 comprises the amino acid sequence RAS, the CDRL3 comprises the amino acid sequence of SEQ ID NO:33, the CDRH1 comprises the amino acid sequence of SEQ ID NO:34, the CDRH2 comprises the amino acid sequence of SEQ ID NO:35, and the CDRH3 comprises the amino acid sequence of SEQ ID NO:36.
Dependencies are inferred from the claim text.